European Primary Care Cardiovascular Society

Disinformation provided by the anti-statin lobby should be fiercely counteracted to protect patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

New method works better than Friedewald formula to calculate LDL-c, also in non-fasting samples

Jan. 4, 2018

The method is an adaptation of the Friedwald formula that incorporates a patient-specific TG:VLDL-ratio. Added accuracy is largest in those with LDL-c <70 mg/dL, without added expense.

ESC/EAS statin eligibility in primary prevention may be expanded to high TG levels

Nov. 29, 2017 - Madsen CM et al., Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

Lower risk of Parkinson’s Disease seen with statin therapy

Nov. 27, 2017 - Poly TN et al., Neuroepidemiology 2017

In a meta-analysis of 13 observational studies, statin use was associated with a modest reduction in the risk of developing Parkinson’s Disease compared with not using statins.

LDL-c lowering for primary prevention at high LDL-c may be initiated without risk assessment, according to WOSCOPS analysis

Nov. 21, 2017 - Vallejo-Vaz AJ et al., Circulation 2017

Men with LDL-c levels ≥190 mg/dL without atherosclerotic CVD, have a 2-fold higher risk of major CV events than would be predicted with a risk calculator.

Early lipid changes ≥5% during psychotropic therapy as a warning sign of future clinically relevant dyslipidemia

Oct. 30, 2017 - Delacrétaz A et al., J Clin Lipidol 2017

These data underscore the importance of prospectively monitoring lipid parameters in all patients starting psychotropic treatment, as these drugs may induce or exacerbate dyslipidemia.

Lipid parameters vary depending on age and sex

Oct. 16, 2017 - Balder JW et al., J Clin Lipidol. 2017

Based on data of the large Dutch Lifelines cohort, reference values have been developed for lipid parameters.

More atherosclerosis seen in those who skip breakfast

Oct. 9, 2017 - Uzhova I et al., J Am Coll Cardiol 2017

Skipping breakfast was associated with a higher risk of non-coronary and generalized atherosclerosis in a sample of asymptomatic individuals in thee prospective PESA study.

Non-statin LDL-lowering drug plus statin protects against stroke in post-ACS patients

Oct. 3, 2017 - Bohula EA et al., Circulation 2017

In the IMPROVE-IT study, the addition of ezetimibe to simvastatin in stabilized post-ACS patients reduced the frequency of ischemic stroke, particularly in patients with a history of prior stroke.

Suboptimal adherence to secondary prevention post-MI increases mortality

Sep. 26, 2017 - Korhonen MJ et al. J Am Coll Cardiol 2017

Post-AMI patients who are adherent to ACE inhibitors/ARBs and statins, but not to beta-blockers, had a similar mortality risk compared with those adherent to all 3 therapies.

Statin treatment effective in pediatric patients with homozygous FH

Sep. 13, 2017 - Stein EA et al. J Am Coll Cardiol. 2017

In children and adolescents with HoFH, rosuvastatin 20 mg alone or in combination with ezetimibe and/or apheresis led to an effective LDL-C reduction, and was well tolerated.

‘The lower the better’ even holds at very low achieved LDL-c

Sep. 21, 2017 - news

ESC 2017 FOURIER trial data show that after 2.2 years of follow-up, very low LDL-c levels are still associated with further reduction of CV events, without an increase in safety events.